Role of dual antiplatelet therapy in symptomatic patients with established vascular disease: Putting the CHARISMA trial into therapeutic perspective

Cardiovascular Drugs and Therapy

Volumn 24, Issue 3, 2010, Pages 207-216

  Boden, William E ^a   Flather, Marcus D ^b   Bhatt, Deepak L ^c  

^a UNIVERSITY AT BUFFALO   (United States)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Aspirin; Cardiovascular disease; Clinical trial design; Clopidogrel; Subgroup analysis

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; FENOFIBRATE; FIBRINOLYTIC AGENT; METOPROLOL; PIOGLITAZONE; PLACEBO;

ACUTE CORONARY SYNDROME; ADD ON THERAPY; ARTERY DISEASE; ATHEROSCLEROTIC PLAQUE; BLEEDING; BLEEDING TENDENCY; CARDIOVASCULAR DISEASE; CAROTID ARTERY OBSTRUCTION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG INDICATION; HEART FAILURE; HEART INFARCTION; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; MONOTHERAPY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; STROKE; SURVIVAL; TRANSIENT ISCHEMIC ATTACK; TRANSLUMINAL CORONARY ANGIOPLASTY; VASCULAR DISEASE;

ASPIRIN; HEMORRHAGE; HUMANS; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; RISK; THROMBOSIS; TICLOPIDINE; TIME FACTORS; VASCULAR DISEASES;

EID: 78149361964     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-010-6245-9     Document Type: Review

References (59)

1. Maggioni AP, Darne B, Atar D, Abadie E, Pitt B, Zannad F. FDA and CPMP rulings on subgroup analyses. Cardiology 2006;107:97-102.
2. Pocock SJ, Assmann SE, Enos LE, Kasten LE. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems. Stat Med. 2002;21:2917-30.
3. Cook DI, Gebski VJ, Keech AC. Subgroup analysis in clinical trials. Med J Aust. 2004;180:289-91.
4. Yusuf S, Wittes J, Probstfield J, Tyroler HA. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA 1991;266:93-8.
5. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706-17.
6. Lagakos SW. The challenge of subgroup analyses-reporting without distorting. N Engl J Med. 2006;354:1667-9.
7. Pfeffer MA, Jarcho JA. The charisma of subgroups and the subgroups of CHARISMA. N Engl J Med. 2006;354:1744-6.
8. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-33.
9. Sabatine MS, Cannon CP, Gibson CM, et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 2005;294:1224-32.
10. Steinhubl SR, Berger PB, Mann 3rd JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411-20.
11. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45, 852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366:1607-21.
12. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352:1179-89.
13. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502.
14. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004;364:331-7.
15. Markus HS, Droste DW, Kaps M, et al. Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial. Circulation 2005;111:2233-40.
16. Wang TH, Bhatt DL, Fox KA, et al. An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. Eur Heart J. 2007;28:2200-7.
17. au. United States Food and Drug Administration. Harmonized guidelines for industry: E9 statistical principles for clinical trials. Rockville: United States Department of Health and Human Services; 1998.
18. European Agency for the Evaluation of Medicinal Products. Points to consider on the clinical development of fibrinolytic medicinal products in the treatment of patients with ST segment elevation acute myocardial infarction (STEMI). London: European Agency for the Development of Medicinal Products; 2003.
19. Brookes ST, Whitley E, Peters TJ, Mulheran PA, Egger M, Davey Smith G. Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives. Health Technol Assess. 2001;5:1-56.
20. Gebski VJ, Keech AC. Statistical methods in clinical trials. Med J Aust. 2003;178:182-4.
21. Hernandez AV, Boersma E, Murray GD, Habbema JD, Steyerberg EW. Subgroup analyses in therapeutic cardiovascular clinical trials: are most of them misleading? Am Heart J. 2006;151:257-64.
22. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ. 2003;326:219.
23. Altman DG, Matthews JN. Statistics notes. Interaction 1: heterogeneity of effects. BMJ. 1996;313:486.
24. Matthews JN, Altman DG. Statistics notes. Interaction 2: compare effect sizes not P values. BMJ. 1996;313:808.
25. Simes RJ, Gebski VJ, Keech AC. Subgroup analysis: application to individual patient decisions. Med J Aust. 2004;180:467-9.
26. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med. 1996;335:217-25.
27. Bourassa MG, Fisher LD, Campeau L, Gillespie MJ, McConney M, Lesperance J. Long-term fate of bypass grafts: the Coronary Artery Surgery Study (CASS) and Montreal Heart Institute experiences. Circulation 1985;72: V71-8.
28. Caracciolo EA, Davis KB, Sopko G, et al. Comparison of surgical and medical group survival in patients with left main equivalent coronary artery disease. Long-term CASS experience. Circulation 1995;91:2335-44.
29. Detre K, Murphy ML, Hultgren H. Effect of coronary bypass surgery on longevity in high and low risk patients. Report from the V. A. Cooperative Coronary Surgery Study. Lancet 1977;2:1243-5.
30. Killip T. The coronary artery surgery study (CASS)-a randomized trial and a registry. Z Kardiol. 1985;74:79-85.
31. Luchi RJ, Scott SM, Deupree RH. Comparison of medical and surgical treatment for unstable angina pectoris. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1987;316:977-84.
32. Scott SM, Luchi RJ, Deupree RH. Veterans Administration Cooperative Study for treatment of patients with unstable angina. Results in patients with abnormal left ventricular function. Circulation 1988;78: I113-21.
33. Sharma GV, Deupree RH, Khuri SF, Parisi AF, Luchi RJ, Scott SM. Coronary bypass surgery improves survival in high-risk unstable angina. Results of a Veterans Administration Cooperative study with an 8-year follow-up. Veterans Administration Unstable Angina Cooperative Study Group. Circulation 1991;84: III260-7.
34. Takaro T, Hultgren HN, Detre KM, Peduzzi P. The Veterans Administration Cooperative Study of stable angina: current status. Circulation 1982;65:60-7.
35. Takaro T, Pifarre R, Fish R. Veterans Administration Cooperative Study of medical versus surgical treatment for stable angina-progress report. Section 3. Left main coronary artery disease. Prog Cardiovasc Dis. 1985;28:229-34.
36. The Veterans Administration Coronary Artery Bypass Surgery Cooperative Study Group. Eleven-year survival in the Veterans Administration randomized trial of coronary bypass surgery for stable angina. N Engl J Med. 1984;311:1333-9.
37. Varnauskas E. European coronary surgery study. Z Kardiol. 1985;74:73-8.
38. Varnauskas E. Survival, myocardial infarction, and employment status in a prospective randomized study of coronary bypass surgery. Circulation 1985;72: V90-V101.
39. Varnauskas E. Twelve-year follow-up of survival in the randomized European Coronary Surgery Study. N Engl J Med. 1988;319:332-7.
40. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39.
41. Jardine AG, Holdaas H, Fellstrom B, et al. Fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post-hoc subgroup analyses of the ALERT Study. Am J Transplant. 2004;4:988-95.
42. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of lowdose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352:1293-304.
43. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-89.
44. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906.
45. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39.
46. European Society of Hypertension, European Society of Cardiology. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:1011-53.
47. The American Heart Association. Updated American heart association statement: patient guidance based on the results of the CHARISMA trial. Dallas: American Heart Association; 2006.
48. SPS3: Secondary Prevention of Smal Subcortical Strokes [SPO-TRIAS]. http://www.strokecenter.org/trials/TrialDetail.aspx? tid=79. Accessed September 8, 2008.
49. Bhatt DL, Flather MD, Hacke W, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007;49:1982-8.
50. Cacoub PP, Bhatt DL, Steg PG, Topol EJ, Creager MA. Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J. 2009;30:192-201.
51. Helton TJ, Bavry AA, Kumbhani DJ, Duggal S, Roukoz H, Bhatt DL. Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: a meta-analysis of randomized trials. Am J Cardiovasc Drugs. 2007;7:289-97.
52. Mooney A. Treating patients with hypertriglyceridaemia saves lives: triglyceride revisited. Curr Med Res Opin. 1999;15:65-77.
53. Tenenbaum A, Fisman EZ, Boyko V, et al. Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate. Arch Intern Med. 2006;166:737-41.
54. Tenkanen L, Manttari M, Kovanen PT, Virkkunen H, Manninen V. Gemfibrozil in the treatment of dyslipidemia: an 18-year mortality follow-up of the Helsinki Heart Study. Arch Intern Med. 2006;166:743-8.
55. Cohn JN, Tognoni G. A randomized trial of the angiotensinreceptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667-75.
56. Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) Investigators. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 2007;353:2001-7.
57. Working Party on Thrombolysis in the Management of Limb Ischemia. Thrombolysis in the management of lower limb peripheral arterial occlusion-a consensus document. Am J Cardiol. 1998;81:207-18.
58. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-61.
59. Erratum in Lancet 2006;368:1415.